Drug Trial Radar · NCT07136285
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Jul 24, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Genelux Corporation
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Conditions
- SCLC, Extensive Stage
Interventions
Olvi-VecDrug
Olvi-Vec will be administered to patient for 3 days during C1
platinum (cisplatin or carboplatin)Drug
After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum (Carboplatin or Cisplatin)will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
EtoposideDrug
After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate safety of Olvi-Vec in patients from day 1 to end of studyTime frame: Interval between the date of enrollment and the date of withdraw and completion of study, up to a maximum of 2 years.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Zhejiang Provincial People's Hospital
Hangzhou, China · Recruiting
Shanghai chest hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.